Novo Nordisk A/S (NOVOBN)
BMV
834.10
+34.10 (+4.26%)
Closed
Aug 24, 2026
Day's Range
805.00834.10
52 wk Range
630.001,179.99
Financial Statements - NOVOBN - Novo Nordisk A/S
Revenue
309.06B
Net Income
102.43BNet Margin 33.1%
EBITDA
150.65B
Free Cash Flow
28.98B
Income Statement
| Period Ending | 2025-12-31 |
|---|---|
| Sales | 309.06B |
| Cost of Goods | 58.78B |
| Gross Profit | 250.27B |
 Operating Expense | - |
| Operating Income | 127.65B |
| Non-Operating Interest | - |
| Other Income Expense | 6.06B |
| Pre Tax Income | 130.54B |
| Income Tax | 28.10B |
| Net Income | 102.43B |
| EPS Basic | 23.06 |
| EPS Diluted | 23.03 |
| Basic Shares Outstanding | 4.44B |
| Diluted Shares Outstanding | 4.44B |
| Ebit | 134.74B |
| Ebitda | 150.65B |
| Net Income Continuous Operations | 102.43B |
| Minority Interests | - |
| Preferred Stock Dividends | - |
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
